Interestingly, we found the largest correlation between ATOX1 expression levels and disease-specific patient survival for stage 1 breast cancer tumors (median DSS of 164 months for low ATOX1 vs. 100 months for high ATOX1, p = 0.008), followed by a less significant correlation for stage 2 tumors (131 vs. 90 months, p = 0.018) and no correlation for stage 3 tumors (Fig. 3). Here, ATOX1 is linked to breast cancer.